Bone pain and white blood cell counts in breast cancer patients
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This study looks at whether a common side effect (bone pain) from a medicine that boosts white blood cells (called G-CSF) is related to the number of neutrophils (a type of white blood cell) in your blood. If you join, you will receive the medicine as part of your normal chemotherapy routine, and the researchers will track your blood counts and any bone pain you experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed breast cancer diagnosis.
- You must be scheduled for chemotherapy that is given every 3 weeks, and you should be expected to receive at least 3 of these treatments.
- You must be between 18 and 69 years old.
- You must weigh at least 45 kg (about 99 pounds).
- You must be able to carry out daily activities with some help (ECOG score of 2 or less).
- You must not have serious heart, lung, liver, or kidney problems, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a medicine called G-CSF (which helps the body make more white blood cells) to antibiotics is better than antibiotics alone for children with cancer who develop a fever and low blood cell counts after chemotherapy.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This study compares two medications—Shengbai Oral Liquid and Leucogen Tablets—to help raise white blood cell counts in breast cancer patients whose counts drop during cancer treatment. Both drugs aim to help your body recover faster and allow you to continue your cancer therapy on schedule.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.